In recent years, from a predominantly diagnostic discipline, nuclear medicine has evolved towards therapeutic applications. Nuclear medicine, in fact, has developed vectorized therapeutic drugs linked to beta or alpha isotopes. The technological evolution of the sector also sees various studies for the use of artificial intelligence for the analysis of images, the processing of the diagnostic result and the consequent personalization of the therapeutic treatment.
These issues will be the key topics of the nineteenth session of the AFI Symposium, entitled “Innovation in special productions“, scheduled for June 7th.
The session will provide an updated overview of all the innovative applications and the sustainability of the applications of technical and medicinal gases in the production processes developed by pharmaceutical companies.
During the session, in fact, there will also be two presentations focused on technology based on suspension plant cell cultures.
The growing interest in these issues is due to the search for alternative sustainable sources of plant ingredients with low environmental impact.
From this perspective, interest in Medicinal Gases is also growing: the challenges for a sustainable world on the one hand, and those of an increasingly technological and personalized medicine on the other, have created and continue to generate opportunities for development and innovation in this area too.
In the below video interview, Floriana Raso, moderator of the session, introduces us to these issues, underlining the pluses of these innovations.
